Peiliang Wang

机构：Shandong University, Shandong Tumor Hospital, Shandong First Medical University · ORCID：0000-0001-7479-0277

发表论文 25 篇 · 总被引 410 次 · h-index 11

代表论文

• Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study (2021 · Frontiers in Oncology · 被引 75)
• A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy (2020 · Therapeutic Advances in Medical Oncology · 被引 59)
• Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases (2020 · Future Oncology · 被引 39)
• Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients (2020 · Frontiers in Oncology · 被引 35)
• CD103+CD8+ T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade (2018 · Cellular Immunology · 被引 25)
• Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition (2024 · OncoImmunology · 被引 24)